RadioClash Inc. — SEC Form D Filing
RadioClash Inc. filed an SEC Form D on November 2, 2026, reporting $100K raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 2, 2026
- Amount reported
- $100K
- Round stage
- Seed
- Industry
- Medical Devices
- Website
- https://www.radioclash.co/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: TEXAS
Problem
Cancers of the liver, pancreas, and bones often present tumors that are inoperable or situated near critical structures where conventional treatments fall short.
Solution
RadioClash is developing an enhanced electroporation therapy platform that uses targeted electrical pulses to create irreversible nanopores in cancer cells, destroying tumors while preserving adjacent blood vessels, nerves, and healthy tissue.
Why now
Advances in image-guided interventional oncology and pulse-field/electroporation engineering allow non-thermal tumor ablation to replace highly morbid surgeries with precise, outpatient-compatible procedures.
Verdict
Investors treated this sub-$100k check as a speculative option on non-thermal pulsed-field ablation, betting that proprietary waveform tuning could crack unresectable margins where thermal methods fail. This cleared because the clinical utility of irreversible electroporation near critical structures was already validated by NanoKnife, not because RadioClash proved differentiated clinical safety or procedural efficiency. Upside remains severely capped by the brutal capital requirements of interventional device commercialization against well-capitalized incumbents who already own the catheter lab real estate.
Source: SEC EDGAR Form D filing